The “Good Clinical Practice Training within the Framework of the New Regulation” program reached a total of 250 participants in 4 different cities in 2024
30.04.2025
The “Good Clinical Practices Training within the Framework of the New Regulation” program, organized in cooperation with the Association of Research-Based Pharmaceutical Companies (AIFD) and Üsküdar University with the contributions of Memorial Hospital, aims to increase the trained workforce in the field of clinical research.
The Association of Research-Based Pharmaceutical Companies (AIFD), which operates to accelerate access to innovative medicines and treatments in Türkiye and to increase Türkiye’s global competitiveness in the field of pharmaceutical research and development (R&D), launched Good Clinical Practices Trainings for people who will take part in different stages of clinical trials in 2024 in cooperation with Üsküdar University and with the contributions of Memorial Hospital. A total of 250 people who participated in the trainings, which aim to increase the competencies of those working in the field of clinical trials and to contribute to the effective execution of the processes, received their certificates of achievement in 2024.
The Good Clinical Practice Trainings, delivered by a strong team consisting of public officials, veteran researchers in the field of clinical trials and industry representatives, were held in Istanbul, Antalya, Ankara and Kayseri. Through this program, AIFD aims to improve Türkiye’s pharma R&D ecosystem and increase the competence of human resources needed in the field of clinical trials.
Drawing attention to the importance of clinical trials for Türkiye and the importance of a trained workforce in this field, AIFD Health Policy Director Dr. Ecz. Nihan Burul Bozkurt shared the following: “The importance of a skilled workforce for the realization of Türkiye’s potential in the field of clinical trials cannot be overstated and is also emphasized in high-level policy documents. In order to conduct more clinical trials in our country, thus ensuring that patients in our country benefit more from clinical trials and have access to the most innovative treatments, a trained workforce operating in this field is essential towards the better management of clinical trial processes. In light of this, we will continue the trainings we started in 2024 with the contributions of Memorial Hospital in order to increase the competencies of professionals working in the field of clinical trials and contribute towards their effective execution. Considering its legislation in line with international regulations, geographical location, population, disease diversity, healthcare infrastructure and qualified healthcare personnel, Türkiye holds significant potential in terms of clinical trials. As an important outcome of this, we’d like to point towards how the clinical trial investment amount of AIFD member companies exceeded the 10 billion TL threshold for the first time in 2023 and the number of clinical trials increased by 9.80% on average in the last four years. In the last 3 years, the clinical trial investment made by AIFD member companies in our country amounted to approximately 1 billion USD. Together with our members, we, as AIFD, will continue to increase the impact and number of collaborations we have developed with all our stakeholders in this field and work to increase the access of Turkish people to the most innovative treatment approaches.”
Emphasizing that the Good Clinical Practice trainings are a very important collaboration to disseminate and refresh clinical trial culture, Memorial Clinical Research Responsible Physician Prof. Dr. Umut Demirci shared the following: “Program participants had the opportunity to receive their training from experienced names in the field, with up-to-date information and real life experiences. In the coming period, we have projects planned both as a continuation of these trainings and aimed towards the dissemination of more advanced clinical trial practices. In addition to this, it’s important to consider academia, industry and health authority collaborations which will increase the awareness of clinical trials in society.”